Cox Grant, Kobayashi Michihiro, Rudd Brian D, Yoshimoto Momoko
Department of Neurology, University of Washington, Seattle, WA, United States.
Department of Investigative Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States.
Front Cell Dev Biol. 2025 Mar 12;13:1555877. doi: 10.3389/fcell.2025.1555877. eCollection 2025.
Hematopoietic stem cells (HSCs) provide all kinds of blood cells for life while maintaining self-renewal ability. During development, HSCs are first produced in the mouse embryo around embryonic day (E) 11. At this time, only one or two transplantable HSCs can be detected per embryo. Then, HSCs migrate to the fetal liver, where the number of HSCs rapidly increases, showing enhanced self-renewal ability. After birth, a transition occurs from the rapidly proliferating fetal HSCs to the more slowly dividing adult HSCs, which ends by 3-4 weeks of age. It is known that fetal HSCs express distinct surface markers and transcriptomes and produce a variety of distinct immune cells that are not made by adult HSCs. Accumulating evidence indicates that the ontogeny of the hematopoietic system is driven by a highly conserved and developmentally regulated RNA binding protein known as . is predominantly expressed in the fetal hematopoietic stem and progenitor cells (HSPCs) and regulates the developmental switch from fetal to adult HSCs. In this review, we will provide an overview of how regulates the expansion and differentiation of HSCs in early life. These insights can be taken into consideration when developing HSC expansion utilizing such physiological characteristics of HSCs.
造血干细胞(HSCs)在维持自我更新能力的同时,为生命提供各种血细胞。在发育过程中,造血干细胞最早于胚胎期(E)第11天左右在小鼠胚胎中产生。此时,每个胚胎中只能检测到一两个可移植的造血干细胞。然后,造血干细胞迁移到胎儿肝脏,在那里造血干细胞的数量迅速增加,显示出增强的自我更新能力。出生后,发生从快速增殖的胎儿造血干细胞向分裂较慢的成体造血干细胞的转变,这一转变在3至4周龄时结束。已知胎儿造血干细胞表达独特的表面标志物和转录组,并产生多种成体造血干细胞无法产生的独特免疫细胞。越来越多的证据表明,造血系统的个体发生是由一种高度保守且受发育调控的RNA结合蛋白驱动的,这种蛋白被称为 。 主要在胎儿造血干细胞和祖细胞(HSPCs)中表达,并调节从胎儿造血干细胞到成体造血干细胞的发育转变。在这篇综述中,我们将概述 如何在生命早期调节造血干细胞的扩增和分化。在利用造血干细胞的这种生理特性开发造血干细胞扩增方法时,可以考虑这些见解。